©2024 Stanford Medicine
Study of SRP-4045 (Casimersen) and SRP-4053 (Golodirsen) in Participants With Duchenne Muscular Dystrophy (DMD)
Recruiting
Trial ID: NCT02500381
Purpose
The main objective of this study is to evaluate the efficacy of SRP-4045 (casimersen) and
SRP-4053 (golodirsen) compared to placebo in participants with DMD with out-of-frame deletion
mutations amenable to skipping exon 45 and exon 53, respectively.
Official Title
A Double-Blind, Placebo-Controlled, Multi-Center Study With an Open-Label Extension to Evaluate the Efficacy and Safety of SRP-4045 and SRP-4053 in Patients With Duchenne Muscular Dystrophy
Stanford Investigator(s)
John W. Day, MD, PhD
Professor of Neurology (Adult Neurology), of Pediatrics (Genetics) and, by courtesy, of Pathology
Kristine Luce
Clinical Professor, Psychiatry and Behavioral Sciences
Eligibility
Inclusion Criteria:
- Genotypically confirmed DMD, with genetic deletion amenable to exon 45 or exon 53
skipping
- Stable dose of oral corticosteroids for at least 24 weeks prior to Week 1, and the
dose is expected to remain constant throughout the study (except for modifications to
accommodate changes in weight).
- Intact right and left biceps or 2 alternative upper muscle groups
- Mean 6MWT ≥300 meters and ≤450 meters
- Stable pulmonary function: forced vital capacity (FVC) ≥50% predicted
Exclusion Criteria:
- Treatment with gene therapy at any time
- Previous treatment with SMT C1100 within 1 week prior to Week 1 and previous treatment
with PRO045 (BMN 045), PRO053 (BMN 053), or PRO051 (BMN 051) within 24 weeks prior to
Week 1
- Current or previous treatment with any other experimental treatment within 12 weeks
prior to Week 1
- Major surgery within 3 months prior to Week 1
- Presence of other clinically significant illness
Other inclusion/exclusion criteria may apply.
Intervention(s):
drug: SRP-4045
drug: SRP-4053
drug: Placebo
Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305